PHARVARIS NV
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company developing small‑molecule therapies for bradykinin‑mediated disorders such as hereditary angioedema (HAE). Investors should know it focuses on oral treatment candidates and early‑to‑mid stage clinical programmes, so value is driven mainly by trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company’s market capitalisation is around $1.54bn, reflecting investor expectations for successful development but also the risks typical of clinical-stage biotech: trial setbacks, regulatory uncertainty and funding needs. Financial runway, data readouts and commercial strategy are key variables to watch. This summary is for educational purposes only and not personal financial advice; investors should assess their own circumstances, consider diversification and be aware that biotech stocks can be volatile and may lose value.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PHARVARIS NV's stock, indicating strong potential for growth.
Financial Health
Pharvaris NV shows strong cash flow and a solid book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PHVS
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Oral therapy focus
Developing oral small‑molecule candidates may expand patient convenience and market reach, though clinical success is not guaranteed and trials carry risk.
Data-driven value
Share price sensitivity is often linked to trial readouts and regulatory milestones; positive results can lift sentiment, but outcomes can vary.
Partnership potential
Collaborations or licensing deals could accelerate development and commercial reach, while financing needs and competition remain key considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
